Call for expressions of interest: Systematic reviews on dose optimization of the first-line TB medicines
22 July 2020, Geneva | The World Health Organization (WHO) Global Tuberculosis Programme has initiated a process for the collection and assessment of evidence on whether the dosing of rifampicin, isoniazid, ethambutol and pyrazinamide requires further optimization to safely improve treatment success and reduce unfavourable treatment outcomes in TB patients on first-line treatment regimens.
WHO's Global TB Programme is seeking support from
independent consultants or group/s of experts with relevant
expertise and experience to undertake systematic reviews to
synthesise the evidence in the above-mentioned topic. The
candidate/s should be able to work independently as well as
interact regularly and collaboratively with the WHO Global TB
Programme team and an external group of technical experts.
The expression of interest with a proposal can be submitted for
systematic reviews covering all four first-line TB medicines
(rifampicin, isoniazid, ethambutol and pyrazinamide) or selected
medicines among them – depending on the interest of the
experts. Please access the
concept note
and
terms of reference
for details of the work and requirements.
Please send your submission to the WHO Global TB Programme at
[email protected]
by 30 August 2020. The proposals received will
go through a detailed review process and the selected
consultants or group/s of experts will be notified on completion
of the review process.
Source:
WHO
